|Awarded On||November 16, 2016|
|Title||High throughput combinatory drug screening for pediatric medulloblastomas with a dysregulated EZH2 pathway|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Donald Parsons|
|Cancer Sites||Brain and Other Nervous System|
Medulloblastoma (MB) is the most common malignant brain tumor that occurs in children. Among the four distinct molecular subgroups, group 3 and 4 MBs often have the poorest prognosis. New therapies are needed. Fortunately, recent studies have found a gene, EZH2, that is frequently activated in the most difficult to treat MBs. While many new EZH2 inhibitors have been developed, the bad news is that they only have limited efficacy as single agent. Our objective is therefore to develop new combinatory therapies that will target EZH2 together with a 2nd gene critical for tumor survival. Based on a genetic concept known as “synthetic lethality”, we hypothesize that simultaneous targeting of two ...